Abstract：
Sodium glucose transporter type 2 (SGLT2) inhibitors have been introduced into human medicine where their beneficial effects go beyond the expected improvement in blood glucose control. These drugs appear to prevent progression of both cardiovascular and kidney diseases, not only in diabetic but also in non-diabetic human patients. As these drugs have received conditional approval for use in diabetic cats and are being used in other veterinary species, the intriguing question as to whether they will have similar cardioprotective and nephroprotective effects in dogs and cats is being asked. The primary mechanism(s) by which SGLT2 inhibitors are cardio- and nephroprotective remain to be fully characterized. This paper reviews these suggested mechanisms in the context of the pathophysiology of progressive cardiovascular and kidney diseases in dogs and cats with the goal of predicting which categories of non-diabetic veterinary patients these drugs might be of most benefit.
摘要：
2型钠葡萄糖转运蛋白（SGLT2）抑制剂已被引入人类医学中，其有益作用超出了预期的血糖控制改善。这些药物似乎可以预防心血管和肾脏疾病的进展，不仅在糖尿病患者中，而且在非糖尿病人类患者中。由于这些药物已获得有条件批准用于糖尿病猫，并且正在用于其他兽类，关于它们是否会在狗和猫中具有类似的心脏保护和肾脏保护作用的有趣问题正在被问到。SGLT2抑制剂具有心脏和肾脏保护性的主要机制仍有待充分表征。本文在狗和猫进行性心血管和肾脏疾病的病理生理学背景下回顾了这些建议的机制，目的是预测哪些类别的非糖尿病兽医患者这些药物可能最有益。
